| Insight Imaging Enters into Agreement to Acquire Eight Imaging Centers (Business Wire) LAKE FOREST, Calif.----InSight Health Services Holdings Corp. today announced that it had signed a definitive agreement to acquire eight imaging centers in the Phoenix, Arizona, El Paso, Texas, and Las Cruces, New Mexico areas from subsidiaries of MedQuest, Inc. and Novant Health, Inc., for a total purchase price of approximately $8.5 million. us.rd.yahoo.com |
Vivus, Arena and Orexigen Investors All Worried About Qnexa FDA Panel Review Joseph Krueger submits: This week is a critical time period for Vivus (VVUS) investors, but it should also be interesting for Arena Pharmaceuticals (ARNA) and Orexigen (OREX) investors, as the three companies all have near term FDA panel reviews and PDUFA dates for their obesity drugs. Vivus’ New Drug Application (NDA) for their weight loss drug, Qnexa, is up for review by the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on July 12 or July 13 (per Bloomberg reported by theflyonthewall.com). This review by outside advisory panelists will foreshadow the likelihood of FDA approval for Qnexa, as the FDA’s actions generally follow with the reviewers opinion. The target date for the FDA to complete its review of the Qnexa NDA is October 28, 2010.Qnexa is a combination of two different generic drugs: Phentermine (formally marketed as Fastin and many other names) and Topiramate (formally marketed as Topamax). Phentermine is an appetite suppressant and stimulant similar to amphetamines. Topiramate is an anticonvulsant drug (designed to stop seizures) and is available in the U.S. in several different formulations generically. Phentermine has typically always been used as an appetite suppressant. Topiramate has been used to treat many different central nervous system (CNS) disorders, including seizure disorders such as epilepsy, biopolar disorder, tremors, obsessive compulsive disorders, behavioral obesity, drug, alcoholism, and smoking cessation. Complete Story » seekingalpha.com |
Put Sellers Bet Allergan Will Hold Firm optionMONSTER submits: Shares of Allergan (AGN) have jumped on this morning's earnings report, and at least one option trader is betting that the stock will hold current levels. The provider of eye care and specialty pharmaceutical products is trading at $64.33, up 5.36 percent this morning after reporting a 36 percent increase in second-quarter net income. AGN broke though $66 earlier in the session but has been declining steadily since. Shares remain in the range that the stock has been bouncing in since October 2009, with the high end set with the two-year high of $66.95 in mid-July.Complete Story » seekingalpha.com |
Positive Data on Vivus’ Weight-Loss Drug Qnexa Zacks.com submits: Vivus Inc. (VVUS) recently announced positive data from a two-year trial of its weight loss, once-daily pill Qnexa. The data, reported from the extended 52-week SEQUEL study, covered 675 overweight or obese patients. The SEQUEL trial followed the 56-week CONQUER trial.The patients who took the highest dose of Qnexa during the total 108 weeks of the study experienced and maintained an average weight loss of 11.4% or 26 pounds. The candidate was well tolerated in the SEQUEL study, with the most common adverse events being constipation, tingling, dry mouth, altered taste and insomnia.Complete Story » seekingalpha.com |
Why I Am Voting For Generex's Reverse Stock Split R.J Steffens submits:Choices are the hinges of destiny ~ Edwin MarkhamOn Friday, Generex (GNBT) Biotechnology announced that approval was given by shareholders to adjourn the Special Meeting until Monday to allow Generex to solicit additional proxies for a reverse stock split proposal. I have voted yes, and I would like to explain my reasoning as we enter the final hours to submit, or resubmit, our proxies. Let's start by showing the proposal being voted upon:The proposal is seeking shareholder approval to amend Generex's Restated Certificate of Incorporation (i) to effect a reverse stock split of the common stock, at an exchange ratio of not less than 1-for-2 and not more than 1-for-10, and while reducing the number of authorized shares of common stock from 750,000,000 to 500,000,000 unless the Board of Directors utilizes a ratio of not more than 1-for-2, in which case, the number of authorized shares of common stock will be maintained at 750,000,000.Complete Story » seekingalpha.com |